首页> 外国专利> Co-administration of cg250 and il-2 or ifn-alpha for threating cancer such as renal cell carcinomas

Co-administration of cg250 and il-2 or ifn-alpha for threating cancer such as renal cell carcinomas

机译:cg250和il-2或ifn-alpha共同给药可用于威胁癌症,例如肾细胞癌

摘要

A method for enhancing the therapeutic effect of cytokine treatment is disclosed. More specifically the present invention relates to a method for administering to a tumor patient a therapeutic dose of cytokine in combination with antibodies directed against the tumor associated antigen carbonic anhydrase IX (CAIX/G250/MN). The improved treatment method is characterized in a significantly reduced cytokine-related toxicity combined with potentiated effectiveness of anti-G250 antibody alone, resulting in a positive therapeutic response with respect to that observed with single anti-tumor agents alone.
机译:公开了一种增强细胞因子治疗的治疗效果的方法。更具体地,本发明涉及向肿瘤患者施用治疗剂量的细胞因子与针对肿瘤相关抗原碳酸酐酶IX(CAIX / G250 / MN)的抗体组合的方法。改进的治疗方法的特征在于与细胞因子相关的毒性显着降低,并且单独的抗G250抗体的效力增强,相对于单独使用单一抗肿瘤剂所观察到的结果,产生了积极的治疗反应。

著录项

  • 公开/公告号US2005261178A1

    专利类型

  • 公开/公告日2005-11-24

    原文格式PDF

  • 申请/专利权人 SVEN OLE WARNAAR;STEFAN ULLRICH;

    申请/专利号US20040517338

  • 发明设计人 SVEN OLE WARNAAR;STEFAN ULLRICH;

    申请日2003-06-23

  • 分类号A61K38/17;

  • 国家 US

  • 入库时间 2022-08-21 21:44:12

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号